A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

Summary

The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.

Timeline

Start

2023-09-21

Primary completion

2024-07-29

Completion

2024-07-29

Drugs

Indications